Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 12/20 | 0.47 |
| ▸ | FNTB | P49356 | 12/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051796 | 0.97 | FNTA (0.43) | FNTAFNTBMETAP2METAP1BACE1 | |
| SCHEMBL30052545 | 0.94 | FNTA (0.50) | FNTAFNTBMETAP2METAP1PGGT1B | |
| SCHEMBL17880750 | 0.94 | FNTA (0.50) | FNTAFNTBMETAP2METAP1PGGT1B | |
| SCHEMBL30052878 | 0.92 | FNTA (0.48) | FNTAFNTBMETAP2METAP1BACE1 | |
| SCHEMBL11668382 | 0.92 | FNTA (0.47) | FNTAFNTBMETAP2METAP1PGGT1B | |
| SCHEMBL30051498 | 0.86 | METAP2 (0.46) | FNTAFNTBMETAP2METAP1PGGT1B | |
| SCHEMBL30143344 | 0.85 | METAP2 (0.42) | FNTAFNTBMETAP2METAP1BACE1 | |
| SCHEMBL30051213 | 0.85 | FNTA (0.44) | FNTAFNTBCTSD | |
| SCHEMBL30051389 | 0.85 | FNTA (0.46) | FNTAFNTBCTSD | |
| SCHEMBL30051938 | 0.85 | ENPEP (0.45) | FNTAFNTBMETAP2METAP1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2025-03-27 | — | — | US | disclosed |
| US-12214059-B2 | Cleavable radioligands for targeting cell surface receptors and uses thereof | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-02-04 | — | — | US | disclosed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2024-11-21 | — | — | US | disclosed |
| CN-118451091-A | Cleavable radioligands for targeting cell surface receptors and uses thereof | 辐联科技香港有限公司 | 2024-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382630-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FNTA 3691/4885FNTB 2699/4885METAP2 766/4885 |
| US-12214059-B2 | Cleavable radioligands for targeting cell surface receptors and uses thereof | ASGR1, GNRHR, SCTR | FNTA 3691/4885FNTB 2699/4885METAP2 766/4885 |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | FNTA 3691/4885FNTB 2699/4885METAP2 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.